25 years of advances in the definition, classification and treatment of status epilepticus

Seizure

Volumn 44, Issue , 2017, Pages 65-73

  Trinka, Eugen ^a,b,c   Kälviäinen, Reetta ^d,e  

^a PARACELSUS MEDICAL UNIVERSITY   (Austria)

^b UNIVERSITY OF SALZBURG   (Austria)

^c UNIVERSITY FOR HEALTH SCIENCES   (Austria)

^d KUOPIO UNIVERSITY HOSPITAL   (Finland)

^e UNIVERSITY OF EASTERN FINLAND   (Finland)

Author keywords

Anesthetics; Antiepileptic drugs; Benzodiazepines; Classification; Status epilepticus

Indexed keywords

CLONAZEPAM; DIAZEPAM; KETAMINE; LACOSAMIDE; LEVETIRACETAM; LORAZEPAM; MAGNESIUM; MIDAZOLAM; PHENOBARBITAL; PHENYTOIN; STEROID; VALPROIC ACID;

AGE; DISEASE CLASSIFICATION; DRUG EFFICACY; ELECTROENCEPHALOGRAM; EPILEPTIC STATE; HUMAN; META ANALYSIS (TOPIC); MULTICENTER STUDY (TOPIC); NERVE CELL NECROSIS; NERVE CELL NETWORK; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL (TOPIC); REVIEW; SYMPTOMATOLOGY; SYSTEMATIC REVIEW (TOPIC); TREATMENT OUTCOME; CLASSIFICATION; CLINICAL TRIAL (TOPIC); ELECTROENCEPHALOGRAPHY; FACTUAL DATABASE; HISTORY; PROCEDURES; STATISTICS AND NUMERICAL DATA; STATUS EPILEPTICUS;

CLINICAL TRIALS AS TOPIC; DATABASES, FACTUAL; ELECTROENCEPHALOGRAPHY; HISTORY, 20TH CENTURY; HISTORY, 21ST CENTURY; HUMANS; STATUS EPILEPTICUS;

EID: 85007162505     PISSN: 10591311     EISSN: 15322688     Source Type: Journal    
DOI: 10.1016/j.seizure.2016.11.001     Document Type: Review

References (99)

1. [1] Betjemann, J.P., Lowenstein, D.H., Status epilepticus in adults. Lancet Neurol 14:June (6) (2015), 615–624 PubMed PMID: 25908090.
2. [2] Kantanen, A.M., Reinikainen, M., Parviainen, I., Ruokonen, E., Ala-Peijari, M., Backlund, T., et al. Incidence and mortality of super-refractory status epilepticus in adults. Epilepsy Behav: E&B 49:August (2015), 131–134 PubMed PMID: 26141934.
3. [3] Trinka, E., Brigo, F., Shorvon, S., Recent advances in status epilepticus. Curr Opin Neurol 29:April (2) (2016), 189–198 PubMed PMID: 26886360.
4. [4] Shorvon, S., Trinka, E., The 5th London-Innsbruck colloquium on status epilepticus and acute seizures. Epilepsy Behav: E&B 49:August (2015), 1–3 PubMed PMID: 26052077.
5. [5] Gastaut, H., Clinical and electroencephalographical classification of epileptic seizures. Epilepsia 11 (1970), 102–113.
6. [6] Gastaut, H., A propos d'une classification symptomatologique des Çtats de mal Çpileptiques. Gastaut, H., Roger, J., Lob, H., (eds.) Les Çtats de mal Çpileptiques, 1967, Masson, Paris, 1–8.
7. [7] Gastaut, H., Clinical and electroencephalographical classification of epileptic seizures. Epilepsia 10:Suppl (1969), S2–S13.
8. [8] Gastaut, H., Classification of status epilepticus. Escueta, A.V.D., Wasterlain, C.G., Treiman, D.M., Porter, R.J., (eds.) Status epilepticus mechanisms of brain damage and treatment advances in neurology, vol 34, 1983, Raven Press, New York, 15–35.
9. [9] Proposal for revised clinical and electroencephalographic classification of epileptic seizures. From the Commission on Classification and Terminology of the International League Against Epilepsy. Epilepsia 22 (1981), 489–501.
10. [10] Treatment of convulsive status epilepticus. Recommendations of the Epilepsy Foundation of America's Working Group on status epilepticus. JAMA 270:7 (1993), 854–859.
11. [11] Treiman, D.M., Meyers, P.D., Walton, N.Y., Collins, J.F., Colling, C., Rowan, A.J., et al. A comparison of four treatments for generalized convulsive status epilepticus. Veterans Affairs Status Epilepticus Cooperative Study Group. N Engl J Med 339:12 (1998), 792–798.
12. [12] Lowenstein, D.H., Bleck, T., Macdonald, R.L., It's time to revise the definition of status epilepticus. Epilepsia 40:1 (1999), 120–122.
13. [13] Trinka, E., Cock, H., Hesdorffer, D., Rossetti, A.O., Scheffer, I.E., Shinnar, S., et al. A definition and classification of status epilepticus-report of the ILAE task force on classification of status epilepticus. Epilepsia 56:October (10) (2015), 1515–1523 PubMed PMID: 26336950.
14. [14] Bauer, G., Trinka, E., Nonconvulsive status epilepticus and coma. Epilepsia 51:February (2) (2010), 177–190 PubMed PMID: 19744116.
15. [15] Trinka, E., Hofler, J., Zerbs, A., Causes of status epilepticus. Epilepsia 53:September (Suppl. 4) (2012), 127–138 PubMed PMID: 22946730.
16. [16] Trinka, E., Leitinger, M., Which EEG patterns in coma are nonconvulsive status epilepticus?. Epilepsy Behav: E&B 49:August (2015), 203–222 PubMed PMID: 26148985.
17. [17] Hirsch, L.J., LaRoche, S.M., Gaspard, N., Gerard, E., Svoronos, A., Herman, S.T., et al. American clinical neurophysiology society's standardized critical care EEG terminology: 2012 version. J Clin Neurophys 30:February (1) (2013), 1–27 PubMed PMID: 23377439.
18. [18] Beniczky, S., Hirsch, L.J., Kaplan, P.W., Pressler, R., Bauer, G., Aurlien, H., et al. Unified EEG terminology and criteria for nonconvulsive status epilepticus. Epilepsia 54:September (Suppl. 6) (2013), 28–29 PubMed PMID: 24001066.
19. [19] Kaplan, P.W., EEG criteria for nonconvulsive status epilepticus. Epilepsia 48:Suppl. 8 (2007), 39–41 PubMed PMID: 18329995.
20. [20] Leitinger, M., Beniczky, S., Rohracher, A., Gardella, E., Kalss, G., Qerama, E., et al. Salzburg consensus criteria for non-convulsive status epilepticus—approach to clinical application. Epilepsy Behav: E&B 49:August (2015), 158–163 PubMed PMID: 26092326.
21. [21] Leitinger, M., Trinka, E., Gardella, E., Rohracher, A., Kalss, G., Qerama, E., et al. Diagnostic accuracy of the Salzburg EEG criteria for non-convulsive status epilepticus: a retrospective study. Lancet Neurol 15:September (10) (2016), 1054–1062 PubMed PMID: 27571157.
22. [22] Rossetti, A.O., Trinka, E., Stahli, C., Novy, J., New ILAE versus previous clinical status epilepticus semiologic classification: analysis of a hospital-based cohort. Epilepsia(June (1)), 2016 PubMed PMID 27249322.
23. [23] Madzar, D., Geyer, A., Knappe, R.U., Gollwitzer, S., Kuramatsu, J.B., Gerner, S.T., et al. Association of seizure duration and outcome in refractory status epilepticus. J Neurol 263:March (3) (2016), 485–491 PubMed PMID: 26725091.
24. [24] Towne, A.R., Pellock, J.M., Ko, D., DeLorenzo, R.J., Determinants of mortality in status epilepticus. Epilepsia 35:1 (1994), 27–34.
25. [25] Alldredge, B.K., Wall, D.B., Ferriero, D.M., Effect of prehospital treatment on the outcome of status epilepticus in children. Pediatr Neurol 12:April (3) (1995), 213–216 PubMed PMID: 7619187.
26. [26] Silbergleit, R., Durkalski, V., Lowenstein, D., Conwit, R., Pancioli, A., Palesch, Y., et al. Intramuscular versus intravenous therapy for prehospital status epilepticus. N Engl J Med 366:February (7) (2012), 591–600 PubMed PMID: 22335736 Pubmed Central PMCID: 3307101.
27. [27] Kortland, L.M., Alfter, A., Bahr, O., Carl, B., Dodel, R., Freiman, T.M., et al. Costs and cost-driving factors for acute treatment of adults with status epilepticus: a multicenter cohort study from Germany. Epilepsia(October), 2016 PubMed PMID 27753082.
28. [28] Kalviainen, R., Status epilepticus treatment guidelines. Epilepsia 48:Suppl. 8 (2007), 99–102 PubMed PMID: 18330014.
29. [29] Shorvon, S., Baulac, M., Cross, H., Trinka, E., Walker, M., The drug treatment of status epilepticus in Europe: consensus document from a workshop at the first London Colloquium on status epilepticus. Epilepsia 49:7 (2008), 1277–1285.
30. [30] Brophy, G.M., Bell, R., Claassen, J., Alldredge, B., Bleck, T.P., Glauser, T., et al. Guidelines for the evaluation and management of status epilepticus. Neurocrit Care 17:August (1) (2012), 3–23 PubMed PMID: 22528274.
31. [31] Jones, S., Pahl, C., Trinka, E., Nashef, L., A protocol for the inhospital emergency drug management of convulsive status epilepticus in adults. Practical Neurol 14:June (3) (2014), 194–197 PubMed PMID: 24810377.
32. [32] Prasad, K., Krishnan, P.R., Al Roomi, K., Sequeira, R., Anticonvulsant therapy for status epilepticus. Br J Clin Pharmacol 63:6 (2007), 640–647.
33. [33] Prasad M, Krishnan PR, Sequeira R, Al-Roomi K. Anticonvulsant therapy for status epilepticus. The Cochrane database of systematic reviews, 2014. 9 CD003723. PubMed PMID: 25207925.
34. [34] Brigo, F., Nardone, R., Tezzon, F., Trinka, E., A common reference-based indirect comparison meta-analysis of buccal versus intranasal midazolam for early status epilepticus. CNS Drugs(August), 2015 PubMed PMID 26293745.
35. [35] Brigo, F., Nardone, R., Tezzon, F., Trinka, E., Nonintravenous midazolam versus intravenous or rectal diazepam for the treatment of early status epilepticus: a systematic review with meta-analysis. Epilepsy Behav: E&B 49:August (2015), 325–336 PubMed PMID: 25817929.
36. [36] McMullan, J., Sasson, C., Pancioli, A., Silbergleit, R., Midazolam versus diazepam for the treatment of status epilepticus in children and young adults: a meta-analysis. Acad Emerg Med 17:June (6) (2010), 575–582 PubMed PMID: 20624136.
37. [37] Sofou, K., Kristjansdottir, R., Papachatzakis, N.E., Ahmadzadeh, A., Uvebrant, P., Management of prolonged seizures and status epilepticus in childhood: a systematic review. J Child Neurol 24:August (8) (2009), 918–926 PubMed PMID: 19332572.
38. [38] Brigo, F., Storti, M., Del Felice, A., Fiaschi, A., Bongiovanni, L.G., IV valproate in generalized convulsive status epilepticus: a systematic review. Eur J Neurol 19:September (9) (2012), 1180–1191 PubMed PMID: 22182304.
39. [39] Brigo, F., Bragazzi, N., Nardone, R., Trinka, E., Direct and indirect comparison meta-analysis of levetiracetam versus phenytoin or valproate for convulsive status epilepticus. Epilepsy Behav: E&B 64:October (Pt A) (2016), 110–115 PubMed PMID: 27736657.
40. [40] Brigo, F., Bragazzi, N.L., Bacigaluppi, S., Nardone, R., Trinka, E., Is intravenous lorazepam really more effective and safe than intravenous diazepam as first-line treatment for convulsive status epilepticus? A systematic review with meta-analysis of randomized controlled trials. Epilepsy Behav: E&B 64:October (Pt A) (2016), 29–36 PubMed PMID: 27732915.
41. [41] Brigo, F., Igwe, S.C., Nardone, R., Tezzon, F., Bongiovanni, L.G., Trinka, E., A common reference-based indirect comparison meta-analysis of intravenous valproate versus intravenous phenobarbitone for convulsive status epilepticus. Epileptic Disord 15:September (3) (2013), 314–323 PubMed PMID: 23981687.
42. [42] Trinka, E., Hofler, J., Leitinger, M., Brigo, F., Pharmacotherapy for status epilepticus. Drugs(August), 2015 PubMed PMID 26310189.
43. [43] Trinka, E., Hofler, J., Leitinger, M., Rohracher, A., Kalss, G., Brigo, F., Pharmacologic treatment of status epilepticus. Expert Opin Pharmacother 17:March (4) (2016), 513–534 PubMed PMID: 26629986.
44. [44] Trinka, E., Hofler, J., Zerbs, A., Brigo, F., Efficacy and safety of intravenous valproate for status epilepticus: a systematic review. CNS Drugs(May), 2014 PubMed PMID: 24806973.
45. [45] Meierkord, H., Boon, P., Engelsen, B., Gocke, K., Shorvon, S., Tinuper, P., et al. EFNS guideline on the management of status epilepticus in adults. Eur J Neurol 17:March (3) (2010), 348–355 PubMed PMID: 20050893.
46. [46] Capovilla, G., Beccaria, F., Beghi, E., Minicucci, F., Sartori, S., Vecchi, M., Treatment of convulsive status epilepticus in childhood: recommendations of the Italian league against epilepsy. Epilepsia 54:October (Suppl. 7) (2013), 23–34 PubMed PMID: 24099053.
47. [47] Trinka, E.B.F., Benzodiazepines used in the treatment of epilepsy. Shorvon, S.P.E., Engel, J., (eds.) The treatment of epilepsy, 4th ed., 2015, Wyley, Chichester, UK, 398–417.
48. [48] Schütz, H., Benzodiazepines II. A handbook. Basic data, analytical methods, pharmacokonetics, and comprehensive literature. 1989, Springer, Heidelberg, New York.
49. [49] Greenblatt, D.J., Divoll, M., Diazepam versus lorazepam: relationship of drug distribution to duration of clinical action. Escueta, A.V.D., Wasterlain, C.G., Treiman, D.M., Porter, R.J., (eds.) Status epileptics mechanisms of brain damage and treatment advances in neruology, vol. 34, 1983, Raven Press, New York, 487–491.
50. [50] Leppik, I.E., Derivan, A.T., Homan, R.W., Walker, J., Ramsay, R.E., Patrick, B., Double-blind study of lorazepam and diazepam in status epilepticus. J Am Med Assoc 249 (1983), 1452–1454.
51. [51] Appleton, R., Sweeney, A., Choonara, I., Robson, J., Molyneux, E., Lorazepam versus diazepam in the acute treatment of epileptic seizures and status epilepticus. Dev Med Child Neurol 37:8 (1995), 682–688.
52. [52] Alldredge, B.K., Gelb, A.M., Isaacs, S.M., Corry, M.D., Allen, F., Ulrich, S., et al. A comparison of lorazepam, diazepam, and placebo for the treatment of out-of-hospital status epilepticus. N Engl J Med 345:9 (2001), 631–637.
53. [53] Chamberlain, J.M., Okada, P., Holsti, M., Mahajan, P., Brown, K.M., Vance, C., et al. Lorazepam vs diazepam for pediatric status epilepticus: a randomized clinical trial. JAMA 311:April (6) (2014), 1652–1660 PubMed PMID: 24756515.
54. [54] Kellinghaus, C., Lang, N., Rossetti, A.O., Ruegg, S., Tilz, C., Trinka, E., et al. Making SENSE–Sustained Effort Network for treatment of status epilepticus as a multicenter prospective registry. BMC Neurol, 15(November (230)), 2015 PubMed PMID: 26554812. Pubmed Central PMCID. 4641362.
55. [55] Ferlisi, M., Hocker, S., Grade, M., Trinka, E., Shorvon, S., International steering committee of the StEp A. Preliminary results of the global audit of treatment of refractory status epilepticus. Epilepsy Behav: E&B 49:August (2015), 318–324 PubMed PMID: 25952268.
56. [56] Cock, H.R., Group, E., Established status epilepticus treatment trial (ESETT). Epilepsia 52:October (Suppl. 8) (2011), 50–52 PubMed PMID: 21967363.
57. [57] Bleck, T., Cock, H., Chamberlain, J., Cloyd, J., Connor, J., Elm, J., et al. The established status epilepticus trial 2013. Epilepsia 54:September (Suppl. 6) (2013), 89–92 PubMed PMID: 24001084.
58. [58] Lang, N., Lange, M., Schmitt, F.C., Bos, M., Weber, Y., Evers, S., et al. Intravenous lacosamide in clinical practice-results from an independent registry. Seizure 39:July (2016), 5–9 PubMed PMID: 27161669.
59. [59] Hofler, J., Trinka, E., Lacosamide as a new treatment option in status epilepticus. Epilepsia 54:March (3) (2013), 393–404 PubMed PMID: 23293881.
60. [60] Sutter, R., Marsch, S., Ruegg, S., Safety and efficacy of intravenous lacosamide for adjunctive treatment of refractory status epilepticus: a comparative cohort study. CNS Drugs 27:April (4) (2013), 321–329 PubMed PMID: 23533010.
61. [61] Garces, M., Villanueva, V., Mauri, J.A., Suller, A., Garcia, C., Lopez Gonzalez, F.J., et al. Factors influencing response to intravenous lacosamide in emergency situations: LACO-IV study. Epilepsy Behav: E&B. 36:July (2014), 144–152 PubMed PMID: 24922617.
62. [62] Mayer, S.A., Claassen, J., Lokin, J., Mendelsohn, F., Dennis, L.J., Fitzsimmons, B.F., Refractory status epilepticus: frequency, risk factors, and impact on outcome. Arch Neurol 59:2 (2002), 205–210.
63. [63] Holtkamp, M., Othman, J., Buchheim, K., Meierkord, H., Predictors and prognosis of refractory status epilepticus treated in a neurological intensive care unit. J Neurol Neurosurg Psychiatry 76:4 (2005), 534–539.
64. [64] Claassen, J., Hirsch, L.J., Emerson, R.G., Mayer, S.A., Treatment of refractory status epilepticus with pentobarbital, propofol, or midazolam: a systematic review. Epilepsia 43:2 (2002), 146–153.
65. [65] Ferlisi, M., Shorvon, S., The outcome of therapies in refractory and super-refractory convulsive status epilepticus and recommendations for therapy. Brain 135:August (Pt 8) (2012), 2314–2328 PubMed PMID: 22577217.
66. [66] Niermeijer, J.M., Uiterwaal, C.S., Van Donselaar, C.A., Propofol in status epilepticus: little evidence, many dangers?. J Neurol 250:10 (2003), 1237–1240.
67. [67] Sutter, R., Marsch, S., Fuhr, P., Kaplan, P.W., Ruegg, S., Anesthetic drugs in status epilepticus: risk or rescue? A 6-year cohort study. Neurology 82:February (8) (2014), 656–664 PubMed PMID: 24319039. Pubmed Central PMCID: 3945664.
68. [68] Fujikawa, D.G., Neuroprotective effect of ketamine administered after status epilepticus onset. Epilepsia 36:2 (1995), 186–195.
69. [69] Borris, D.J., Bertram, E.H., Kapur, J., Ketamine controls prolonged status epilepticus. Epilepsy Res 42:2–3 (2000), 117–122.
70. [70] Kapur, J., Coulter, D.A., Experimental status epilepticus alters gamma-aminobutyric acid type A receptor function in CA1 pyramidal neurons. Ann Neurol 38:6 (1995), 893–900.
71. [71] Mazarati, A.M., Wasterlain, C.G., N-methyl-D-asparate receptor antagonists abolish the maintenance phase of self-sustaining status epilepticus in rat. Neurosci Lett 265:3 (1999), 187–190.
72. [72] Gaspard, N., Foreman, B., Judd, L.M., Brenton, J.N., Nathan, B.R., McCoy, B.M., et al. Intravenous ketamine for the treatment of refractory status epilepticus: a retrospective multicenter study. Epilepsia 54:August (8) (2013), 1498–1503 PubMed PMID: 23758557. Pubmed Central PMCID: 3731413.
73. [73] Synowiec, A.S., Singh, D.S., Yenugadhati, V., Valeriano, J.P., Schramke, C.J., Kelly, K.M., Ketamine use in the treatment of refractory status epilepticus. Epilepsy Res 105:July (1–2) (2013), 183–188 PubMed PMID: 23369676.
74. [74] Basha, M.M., Alqallaf, A., Shah, A.K., Drug-induced EEG pattern predicts effectiveness of ketamine in treating refractory status epilepticus. Epilepsia 56:April (4) (2015), e44–e48 PubMed PMID: 25759241.
75. [75] Walker, M.C., Howard, R.S., Smith, S.J., Miller, D.H., Shorvon, S.D., Hirsch, N.P., Diagnosis and treatment of status epilepticus on a neurological intensive care unit. QJM 89:12 (1996), 913–920.
76. [76] Kofke, W.A., Bloom, M.J., Van Cott, A., Brenner, R.P., Electrographic tachyphylaxis to etomidate and ketamine used for refractory status epilepticus controlled with isoflurane. J Neurosurg Anesthesiol 9:July (3) (1997), 269–272 PubMed PMID: 9239591.
77. [77] Ubogu, E.E., Sagar, S.M., Lerner, A.J., Maddux, B.N., Suarez, J.I., Werz, M.A., Ketamine for refractory status epilepticus: a case of possible ketamine-induced neurotoxicity. Epilepsy Behav 4:1 (2003), 70–75.
78. [78] Robakis, T.K., Hirsch, L.J., Literature review, case report, and expert discussion of prolonged refractory status epilepticus. Neurocrit Care 4:1 (2006), 35–46.
79. [79] Pruss, H., Holtkamp, M., Ketamine successfully terminates malignant status epilepticus. Epilepsy Res 82:December (2–3) (2008), 219–222 PubMed PMID: 18804344.
80. [80] Yeh, P.S., Shen, H.N., Chen, T.Y., Oral ketamine controlled refractory nonconvulsive status epilepticus in an elderly patient. Seizure 20:November (9) (2011), 723–736 PubMed PMID: 21724423.
81. [81] Kramer, A.H., Early ketamine to treat refractory status epilepticus. Neurocrit care 16:April (2) (2012), 299–305 PubMed PMID: 22237581.
82. [82] Zeiler, F.A., Kaufmann, A.M., Gillman, L.M., West, M., Silvaggio, J., Ketamine for medically refractory status epilepticus after elective aneurysm clipping. Neurocrit Care 19:August (1) (2013), 119–124 PubMed PMID: 23702695.
83. [83] Shrestha, G.S., Joshi, P., Chhetri, S., Karn, R., Acharya, S.P., Intravenous ketamine for treatment of super-refractory convulsive status epilepticus with septic shock: a report of two cases. Indian J Crit Care Med 19:May (5) (2015), 283–285 PubMed PMID: 25983437. Pubmed Central PMCID: 4430749.
84. [84] Hsieh, C.Y., Sung, P.S., Tsai, J.J., Huang, C.W., Terminating prolonged refractory status epilepticus using ketamine. Clin Neuropharmacol 33:May (3) (2010), 165–167 PubMed PMID: 20098301.
85. [85] White, P.F., Schuttler, J., Shafer, A., Stanski, D.R., Horai, Y., Trevor, A.J., Comparative pharmacology of the ketamine isomers. Studies in volunteers. Br J Anaesth 57:February (2) (1985), 197–203 PubMed PMID: 3970799.
86. [86] Engelhardt, W., Stahl, K., Marouche, A., Hartung, E., Recovery time after (S)-ketamine or ketamine racemate. Recovery time after short anesthesia in volunteers. Anaesthesist 47:March (3) (1998), 184–192 PubMed PMID: 9567151 Aufwachzeit nach (S)-Ketamin- oder Ketamin-Razemat. Aufwachzeit nach Kurznarkosen bei Probanden.
87. [87] Hofler, J., Rohracher, A., Kalss, G., Zimmermann, G., Dobesberger, J., Pilz, G., et al. (S)-Ketamine in refractory and super-refractory status epilepticus: a retrospective study. CNS Drugs 30:September (9) (2016), 869–876 PubMed PMID: 27465262. Pubmed Central PMCID: 4996879.
88. [88] Hanada, T., Hashizume, Y., Tokuhara, N., Takenaka, O., Kohmura, N., Ogasawara, A., et al. Perampanel: a novel, orally active, noncompetitive AMPA-receptor antagonist that reduces seizure activity in rodent models of epilepsy. Epilepsia 52:July (7) (2011), 1331–1340 PubMed PMID: 21635236.
89. [89] Rogawski, M.A., Hanada, T., Preclinical pharmacology of perampanel, a selective non-competitive AMPA receptor antagonist. Acta Beurol Scand Suppl 197 (2013), 19–24 PubMed PMID: 23480152. Pubmed Central PMCID: 4506647.
90. [90] Rohracher, A., Hofler, J., Kalss, G., Leitinger, M., Kuchukhidze, G., Deak, I., et al. Perampanel in patients with refractory and super-refractory status epilepticus in a neurological intensive care unit. Epilepsy Behav: E&B 49:August (2015), 354–358 PubMed PMID: 25962657.
91. [91] Redecker, J., Wittstock, M., Benecke, R., Rosche, J., Efficacy of perampanel in refractory nonconvulsive status epilepticus and simple partial status epilepticus. Epilepsy Behav: E&B 45:April (2015), 176–179 PubMed PMID: 25819947.
92. [92] Rosche, J., Kampf, C., Benecke, R., Possible effect of perampanel on focal status epilepticus after generalized tonic-clonic status epilepticus. Acta Neurol Belgica 114:September (3) (2014), 243–244 PubMed PMID: 23801431.
93. [93] Naylor, D.E., Liu, H., Wasterlain, C.G., Trafficking of GABA(A) receptors, loss of inhibition, and a mechanism for pharmacoresistance in status epilepticus. J Neurosci 25:34 (2005), 7724–7733.
94. [94] Naylor, D.E., Wasterlain, C.G., GABA synapses and the rapid loss of inhibition to dentate gyrus granule cells after brief perforant-path stimulation. Epilepsia 46:Suppl. 5 (2005), 142–147.
95. [95] Rogawski, M.A., Loya, C.M., Reddy, K., Zolkowska, D., Lossin, C., Neuroactive steroids for the treatment of status epilepticus. Epilepsia 54:September (Suppl. 6) (2013), 93–98 PubMed PMID: 24001085. Pubmed Central PMCID: 3772544.
96. [96] Broomall, E., Natale, J.E., Grimason, M., Goldstein, J., Smith, C.M., Chang, C., et al. Pediatric super-refractory status epilepticus treated with allopregnanolone. Ann Neurol 76:December (6) (2014), 911–915 PubMed PMID: 25363147. Pubmed Central PMCID: 4534165.
97. [97] Shorvon, S., Ferlisi, M., The treatment of super-refractory status epilepticus: a critical review of available therapies and a clinical treatment protocol. Brain 134:October (Pt 10) (2011), 2802–2818 PubMed PMID: 21914716.
98. [98] Vezzani, A., Ruegg, S., The pivotal role of immunity and inflammatory processes in epilepsy is increasingly recognized: introduction. Epilepsia 52:May (Suppl. 3) (2011), 1–4 PubMed PMID: 21542838.
99. [99] Graus, F., Titulaer, M.J., Balu, R., Benseler, S., Bien, C.G., Cellucci, T., et al. A clinical approach to diagnosis of autoimmune encephalitis. Lancet Neurol 15:April (4) (2016), 391–404 PubMed PMID: 26906964 Pubmed Central PMCID: 5066574.